- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
New Malaria Vaccine Demonstrates 87% Efficacy in Clinical Trial

The novel genetically attenuated whole-parasite PfSPZ-LARC2 malaria vaccine demonstrated 87% efficacy in preventing malaria infection in a phase 1 clinical trial.
Among 22 participants exposed to live malaria parasites 12–16 weeks after their last vaccine dose, only 2 of 15 vaccinated individuals developed an infection, compared with all 7 participants receiving placebo.
The vaccine was also safe and well tolerated; all infected participants received prompt treatment. PfSPZ-LARC2 shows promising potential for malaria prevention, warranting further clinical trials to establish its efficacy, safety and long-term protection in larger populations.
These breakthrough findings were presented today at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D.C. They were reported by Dr. Sean C. Murphy, professor of laboratory medicine and pathology at the University of Washington School of Medicine and medical director, Department of Laboratories, Seattle Children’s Hospital.
The recently completed trial was conducted by UW Medicine and its partners as part of the Infectious Diseases Clinical Research Consortium, or IDCRC, and was sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases.
The trial began enrollment in the summer of 2025. The study's co-principal investigators, along with Murphy, are Dr. Jim Kublin of the Fred Hutch Cancer Center’s Vaccine and Infectious Disease Division, and Dr. R. Scott McClelland, professor of medicine, epidemiology and global health at UW School of Medicine, who led clinical site operations at Harborview Medical Center's Virology Research Clinic.
Because there are over 600,000 deaths worldwide each year from malaria, vaccines that completely block infection — rather than just reduce symptom severity — are urgently needed.
The attenuated PfLARC2 strain was created in Dr. Stefan Kappe’s laboratory at Seattle Children’s. Kappe is now director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine in Baltimore.Co-inventors also include former lab member Dr. Debashree Goswami and Dr. Ashley Vaughan at Seattle Children’s. The strain was further developed, manufactured, and advanced to the clinical stage by Sanaria Inc.
“We engineered the PfLARC2 strain with the goal to have a safe vaccine that stimulates a superior response against malaria parasite infection in the liver. It is truly rewarding to see that this vaccine is safe and how well it has protected against challenge with a highly divergent malaria strain in the Seattle trial,” Kappe said.
This live-attenuated vaccine exposes the human immune system to a wide assortment of parasite proteins and grows like a normal malaria parasite until two genetic deletions in the vaccine safely halt the parasite's growth during its liver stage.
"This study was made possible by the culmination of decades' worth of research on the biology of Plasmodium parasites and the maturation of genetic engineering technologies that allowed scientists to modify the parasite genome to make it safe for use in humans and yet tuned just right to induce strong protective immune responses," Murphy said.
The study’s "challenge" design meant that the vaccine’s efficacy was tested by deliberately exposing vaccinated and placebo-treated participants to live malaria parasites under carefully controlled conditions. This study’s test of efficacy was notable because of the long gap between immunization and challenge (12 to 16 weeks) and the use of a variant malaria strain in the challenge itself. This required the PfSPZ-LARC2 Vaccine to achieve durable, cross-strain immunity in order to provide protection.
The ability to protect across variant strains is important since the P. falciparum parasite is geographically diverse, and it is important for the vaccine to be protective everywhere that malaria is transmitted. In this trial, the vaccine strain used is from West Africa, and the challenge strain is from Brazil.
"It takes a strong and well-coordinated clinical trial team with excellent laboratory resources and with highly engaged and committed research participants to carry out these kind of studies," McClelland said.
Kublin noted that Seattle has a unique testing facility for participants and an altruistic study population that make human challenge studies possible. "Our teams at UW Medicine and Fred Hutch have been conducting malaria human challenge studies since 2011 and have used the model to provide important insights about new drugs and vaccines," Kublin said.
Highly sensitive assaying for these studies is provided by the UW Medicine Malaria Molecular Diagnostic Laboratory, which Murphy directs.
"We look forward to continuing to advance this vaccine and other promising products that can combat malaria using our unique clinical trial resources here in Seattle," Murphy said.
Reference:
Malaria vaccine shows 87% efficacy in clinical trial, University of Washington School of Medicine/UW Medicine, Meeting:American Society of Tropical Medicine and Hygiene Annual Meeting 2026.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

